【技术实现步骤摘要】
【国外来华专利技术】—种通过检测生物液体中miRNA来鉴定患早期肺癌的无症状高风险个体的方法
本专利技术涉及诊断和预后肺癌的方法和途径。更具体地,本专利技术涉及检测无症状对象中早期肺癌的生物液体miRNA测试。
技术介绍
肺癌,特别是非小细胞肺癌(NSCLC )是全球癌症死亡的首要元凶,主要由于缺乏有效的早期诊断工具。早期疾病(I期)就诊断出的患者预后相当好(5年后存活率为60-80%3)。不幸的是,所有NSCLC中只有20-25%被早期诊断4’5。烟草接触是肺癌的主要风险因素6。甚至在原吸烟者中,烟草相关的风险仍长期居高不下7。因此,早期检测NSCLC的有效工具,尤其在高风险个体中,极其需要。低剂量螺旋计算机断层扫描(LD-CT)已在前瞻性观察试验中测试,并已证明是小结节(甚至〈5_)和无症状肺癌诊断(主要(67-85%)在I期^1°)的有效检测方法。对于每年LD-CT筛选是否降低晚期疾病(II1-1V期)诊断和肺癌死亡n_13存在争论,并且以下情况的可能性已增加=LD-CT筛选可能导致过度诊断和过度治疗生物无痛性癌症,所述癌症可能很少达到临床相关性或造成对象的健康风险14’15。然而,最近已确定LD-CT的有效性,其作为一种大型随机试验(国家肺筛选试验16)基于“目前积累数据对研究的主要问题提供了统计学上有说服力的答案”过早停止(http: //www.cancer, gov/newscenter/pressreleases/NLSTresultsRelease)。如果早期诊断的确是降低肺癌死亡的有效方法,那么开发诊断性血液测试对执行有效人口筛选而言极其相关。特异 ...
【技术保护点】
一种诊断无症状对象中肺肿瘤,或区分对象中良性和恶性肺结节,或对象中肺肿瘤预后的方法,包括以下步骤:a)在来自所述对象的生物液体样品中检测包含在下列34个miRNA中的至少5个miRNA:hsa‑let‑7a(MIMAT0000062,SEQ ID No.1);hsa‑let‑7b(MIMAT0000063,SEQ ID No.2);hsa‑let‑7d(MIMAT0000065,SEQ ID No.3);hsa‑miR‑103(MIMAT0000101,SEQ ID No.4);hsa‑miR‑126(MIMAT0000445,SEQ ID No.5);hsa‑miR‑133b(MIMAT0000770,SEQ ID No.6);hsa‑miR‑139‑5p(MIMAT0000250,SEQ ID No.7);hsa‑miR‑140‑5p(MIMAT0000431,SEQ ID No.8);hsa‑miR‑142‑3p(MIMAT0000434,SEQ ID No.9);hsa‑miR‑142‑5p(MIMAT0000433,SEQ ID No.10);hsa‑miR‑148a(MIM ...
【技术特征摘要】
【国外来华专利技术】2011.03.30 EP 11160387.4;2010.12.30 US 61/428,3631.一种诊断无症状对象中肺肿瘤,或区分对象中良性和恶性肺结节,或对 象中肺肿瘤预后的方法,包括以下步骤: a)在来自所述对象的生物液体样品中检测包含在下列34个miRNA中的至少5个miRNA:hsa-let-7a(MIMAT0000062, SEQ ID N0.1);hsa-let-7b(MIMAT0000063, SEQ ID N0.2);hsa-let-7d(MIMAT0000065, SEQ ID N0.3); hsa-miR-103(MIMAT0000101, SEQ ID N0.4);hsa-miR-126(MIMAT0000445, SEQ ID N0.5);hsa-miR-133b(MIMAT0000770, SEQ ID N0.6);hsa-miR-139-5p(MIMAT0000250, SEQ ID N0.7);hsa-miR-140-5p(MIMAT0000431, SEQ ID N0.8);hsa-miR-142-3p(MIMAT0000434, SEQ ID N0.9);hsa-miR-142-5p(MIMAT0000433, SEQ ID N0.10);hsa-miR-148a(MIMAT0000243, SEQ ID N0.11);hsa-miR-148b(MIMAT0000759, SEQ ID N0.12);hsa-miR-17-5p(MIMAT0000070, SEQ ID N0.13);hsa-miR-191(MIMAT0000440, SEQ ID N0.14);hsa-miR-22(MIMAT0000077, SEQ ID N0.15);hsa-miR-223(MIMAT0000280, SEQ ID N0.16);hsa-miR-26a(MIMAT0000082, SEQ ID N0.17);hsa-miR-26b(MIMAT0000083, SEQ ID N0.18);hsa-miR-28-5p(MIMAT0000085, SEQ ID N0.19);hsa-miR-29a(MIMAT0000086, SEQ ID N0.20);hsa-miR-30b(MIMAT0000420, SEQ ID N0.21);hsa-miR-30c(MIMAT0000244, SEQ ID N0.22);hsa-miR-32(MIMAT0000090, SEQ ID N0.23);hsa-miR-328(MIMAT0000752, SEQ ID N0.24);hsa-miR-331-3p(MIMAT0000760, SEQ ID N0.25);hsa-miR-342-3p(MIMAT0000753, SEQ ID N0.26);hsa-miR-374a(MIMAT0000727, SEQ ID N0.27);hsa-miR-376a(MIMAT0000729, SEQ ID N0.28);hsa-miR-432-staR(MIMAT0002815, SEQ ID N0.29);hsa-miR-484(MIMAT0002174, SEQ ID N0.30);hsa-miR-486-5p(MIMAT0002177, SEQ ID N0.31);hsa-miR-566(MIMAT0003230, SEQ ID N0.32);hsa-miR-92a(MIMAT0000092, SEQ ID N0.33);hsa-miR-98(MIMAT0000096, SEQ ID N0.34); 以及b)将所述miRNA量与合适对照比较,其中所述比较可以诊断或预后肺肿瘤,或区分良性和恶性肺结节。2.如权利要求1所述的方法,其特征在于,所述至少5个miRNA是: hsa-let-7a(MIMAT0000062, SEQ ID N0.1);hsa-miR-133b(MIMAT0000770, SEQ ID N0.6);hsa-miR-342-3p(MIMAT0000753, SEQ ID N0.26);hsa-miR-486-5p(MIMAT0002177, SEQ ID N0.31); 且一个miRNA包含在下组: hsa-let-7b(MIMAT0000063, SEQ ID N0.2); hsa-let-7d(MIMAT0000065, SEQ ID N0.3); hsa-miR-103(MIMAT 0000101, SEQ ID N0.4); hsa-miR-126(MIMAT0000445, SEQ ID N0.5); hsa-miR-139-5p(MIMAT0000250, SEQ ID N0.7); hsa-miR-140-5p(MIMAT0000431, SEQ ID N0.8); hsa-miR-142-3p(MIMAT0000434, SEQ ID N0.9); hsa-miR-142-5p(MIMAT0000433, SEQ ID N0.10); hsa-miR-148a(MIMAT0000243, SEQ ID N0.11); hsa-miR-148b(MIMAT0000759, SEQ ID N0.12); hsa-miR-17-5p(MIMAT0000070, SEQ ID N0.13); hsa-miR-191(MIMAT0000440, SEQ ID N0.14); hsa-miR-22(MIMAT0000077, SEQ ID N0.15); hsa-miR-223(MIMAT0000280, SEQ ID N0.16); hsa-miR-26a(MIMAT0000082, SEQ ID N0.17); hsa-miR-26b(MIMAT0000083, SEQ ID N0.18); hsa-miR-28-5p(MIMAT0000085, SEQ ID N0.19); hsa-miR-29a(MIMAT0000086, SEQ ID N0.20); hsa-miR-30b(MIMAT0000420, SEQ ID N0.21); hsa-miR-30c(MIMAT0000244, SEQ ID N0.22); hsa-miR-32(MIMAT0000090, SEQ ID N0.23); hsa-miR-328(MIMAT0000752, SEQ ID N0.24); hsa-miR-331-3p(MIMAT0000760, SEQ ID N0.25); hsa-miR-374a(MIMAT0000727, SEQ ID N0.27); hsa-miR-376a(MIMAT0000729, SEQ ID N0.28); hsa-miR-432-staR(MIMAT0002815, SEQ ID N0.29); hsa-miR-484(MIMAT0002174, SEQ ID N0.30); hsa-miR-566(MIMAT0003230, SEQ ID N0.32); hsa-miR-92a(MIMAT0000092, SEQ ID N0.33); hsa-miR-98(MIMAT0000096, SEQ ID N0.34)。3.如权利要求1所述的方法,其特征在于,所述至少5个miRNA是:hsa-miR-140-5p(MIMAT0000431, SEQ ID N0.8);hsa-miR-30c(MIMAT0000244, SEQ ID N0.22);hsa-miR-374a(MIMAT0000727, SEQ ID N0.27);hsa-let-7b(MIMAT0000063, SEQ ID N0.2);且一个miRNA包含在下组:hsa-let-7a(MIMAT0000062, SEQ ID N0.1);hsa-let-7d(MIMAT0000065, SEQ ID N0.3);hsa-miR-103(MIMAT0000101, SEQ ID N0.4);hsa-miR-126(MIMAT0000445, SEQ ID N0.5);hsa-miR-133b(MIMAT0000770, SEQ ID N0.6);hsa-miR-139-5p(MIMAT0000250, SEQ ID N0.7);hsa-miR-142-3p(MIMAT0000434, SEQ ID N0.9);hsa-miR-142-5p(MIMAT0000433, SEQ ID N0.10);hsa-miR-148a(MIMAT0000243, SEQ ID N0.11);hsa-miR-148b(MIMAT0000759, SEQ ID N0.12);hsa-miR-17-5p(MIMAT0000070, SEQ ID N0.13);hsa-miR-191(MIMAT0000440, SEQ ID N0.14);hsa-miR-22(MIMAT0000077, SEQ ID N0.15);hsa-miR-223(MIMAT0000280, SEQ ID N0.16);hsa-miR-26a(MIMAT0000082, SEQ ID N0.17);hsa-miR-26b(MIMAT0000083, SEQ ID N0.18);hsa-miR-28-5p(MIMAT0000085, SEQ ID N0.19);hsa-miR-29a(MI MAT0000086, SEQ ID N0.20);hsa-miR-30b(MIMAT0000420, SEQ ID N0.21);hsa-miR-32(MIMAT0000090, SEQ ID N0.23);hsa-miR-328(MIMAT0000752, SEQ ID N0.24);hsa-miR-331-3p(MIMAT0000760, SEQ ID N0.25);hsa-miR-342-3p(MIMAT0000753, SEQ ID N0.26);hsa-miR-376a(MIMAT0000729, SEQ ID N0.28);hsa-miR-432-staR(MIMAT0002815, SEQ ID N0.29);hsa-miR-484(MIMAT0002174, SEQ ID N0.30);hsa-miR-486-5p(MIMAT0002177, SEQ ID N0.31);hsa-miR-566(MIMAT0003230, SEQ ID N0.32);hsa-miR-92a(MIMAT0000092, SEQ ID N0.33);hsa-miR-98(MIMAT0000096, SEQ ID N0.34)。4.如权利要求1或2所述的方法,其特征在于,所述至少5个miRNA是:hsa-let-7a(MIMAT0000062, SEQ ID N0.1);hsa-miR-133b(MIMAT0000770, SEQ ID N0.6);hsa-miR-342-3p(MIMAT0000753, SEQ ID N0.26);hsa-miR-486-5p(MIMAT0002177, SEQ ID N0.31);hsa-miR-139-5p(MIMAT0000250, SEQ ID N0.7); 或者hsa-let-7a(MIMAT0000062, SEQ ID N0.1); hsa-miR-133b(MIMAT0000770, SEQ ID N0.6);hsa-miR-342-3p(MIMAT0000753, SEQ ID N0.26);hsa-miR-486-5p(MIMAT0002177, SEQ ID N0.31);hsa-miR-223(MIMAT0000280, SEQ ID N0.16); 或者hsa-let-7a(MIMAT0000062, SEQ ID N0.1);hsa-miR-133b(MIMAT0000770, SEQ ID N0.6);hsa-miR-342-3p(MIMAT0000753, SEQ ID N0.26);hsa-miR-486-5p(MIMAT0002177, SEQ ID N0.31);hsa-let-7b(MIMAT0000063, SEQ ID N0.2)。5.如权利要求1或3所述的方法,其特征在于,所述至少5个miRNA是: hsa-miR-140-5p(MIMAT0000431, SEQ ID N0.8);hsa-miR-30c(MIMAT0000244, SEQ ID N0.22);hsa-miR-374a(MIMAT0000727, SEQ ID N0.27);hsa-let-7b(MIMAT0000063, SEQ ID N0.2);hsa-miR-223(MIMAT0000280, SEQ ID N0.16); 或者hsa-miR-140-5p(MIMAT0000431, SEQ ID N0.8);hsa-miR-30c(MIMAT0000244, SEQ ID N0.22);hsa-miR-374a(MIMAT0000727, SEQ ID N0.27);hsa-let-7b(MIMAT0000063, SEQ ID N0.2);hsa-let-7d(MIMAT0000065, SEQ ID N0.3)。6.如权利要求1或2所述的方法,其特征在于,所述检测步骤a)包括在来自所述对象的生物液体样品中检测至少10个miRNA,其中所述10个miRNA是:hsa-let-7a(MIMAT0000062, SEQ ID N0.1);hsa-miR-133b(MIMAT0000770, SEQ ID N0.6);hsa-miR-342-3p(MIMAT0000753, SEQ ID N0.26);hsa-miR-486-5p(MIMAT0002177, SEQ ID N0.31); 且其它6个miRNA包含在下组中: hsa-let-7b(MIMAT0000063, SEQ ID N0.2); hsa-let-7d(MIMAT0000065, SEQ ID N0.3); hsa-miR-103(MIMAT0000101, SEQ ID N0.4); hsa-miR-126(MIMAT0000445, SEQ ID N0.5); hsa-miR-139-5p(MIMAT0000250, SEQ ID N0.7); hsa-miR-140-5p(MIMAT0000431, SEQ ID N0.8);hsa-miR-142-3p(MIMAT0000434, SEQ ID N0.9);hsa-miR-142-5p(MIMAT0000433, SEQ ID N0.10);hsa-miR-148a(MIMAT0000243, SEQ ID N0.11);hsa-miR-148b(MIMAT0000759, SEQ ID N0.12);hsa-miR-17-5p(MIMAT0000070, SEQ ID N0.13);hsa-miR-191(MIMAT0000440, SEQ ID N0.14);hsa-miR-22(MIMAT0000077, SEQ ID N0.15);hsa-miR-223(MIMAT0000280, SEQ ID N0.16);hsa-miR-26a(MIMAT0000082, SEQ ID N0.17);hsa-miR-26b(MIMAT0000083, SEQ ID N0.18);hsa-miR-28-5p(MIMAT 0000085, SEQ ID N0.19);hsa-miR-29a(MIMAT0000086, SEQ ID N0.20);hsa-miR-30b(MIMAT0000420, SEQ ID N0.21);hsa-miR-30c(MIMAT0000244, SEQ ID N0.22);hsa-miR-32(MIMAT0000090, SEQ ID N0.23);hsa-miR-328(MIMAT0000752, SEQ ID N0.24);hsa-miR-331-3p(MIMAT0000760, SEQ ID N0.25);hsa-miR-374a(MIMAT0000727, SEQ ID N0.27);hsa-miR-376a(MIMAT0000729, SEQ ID N0.28);hsa-miR-432-staR(MIMAT0002815, SEQ ID N0.29);hsa-miR-484(MIMAT0002174, SEQ ID N0.30);hsa-miR-566(MIMAT0003230, SEQ ID N0.32);hsa-miR-92a(MIMAT0000092, SEQ ID N0.33);hsa-miR-98(MIMAT0000096, SEQ ID N0.34)。7.如权利要求6所述的方法,其特征在于,所述至少10个miRNA是: hsa-let-7a(MIMAT0000062, SEQ ID N0.1);hsa-miR-133b(MIMAT0000770, SEQ ID N0.6);hsa-miR-139-5p(MIMAT0000250, SEQ ID N0.7);hsa-miR-140-5p(MIMAT0000431, SEQ ID N0.8);hsa-miR-148b(MIMAT0000759, SEQ ID N0.12);hsa-miR-26b(MIMAT0000083, SEQ ID N0.18);hsa-miR-32(MIMAT0000090, SEQ ID N0.23);hsa-miR-342-3p(MIMAT0000753, SEQ ID N0.26);hsa-miR-432-staR(MIMAT0002815, SEQ ID N0.29);hsa-miR-486-5p(MIMAT0002177, SEQ ID N0.31)?8.如权利要求1或3所述的方法,其特征在于,所述检测步骤a)包括在来自所述对象的生物液体样品中检测至少10个miRNA,其中所述至少10个miRNA是:hsa-miR-140-5p(MIMAT0000431, SEQ ID N0.8);hsa-miR-30c(MIMAT0000244, SEQ ID N0.22);hsa-miR-374a(MIMAT0000727, SEQ ID N0.27);hsa-let-7b(MIMAT0000063, SEQ ID N0.2); 且其它6个miRNA包含在下组中: hsa-let-7a(MIMAT0000062, SEQ ID N0.1); hsa-let-7d(MIMAT0000065, SEQ ID N0.3); hsa-miR-103(MIMAT0000101, SEQ ID N0.4); hsa-miR-126(MIMAT0000445, SEQ ID N0.5); hsa-miR-133b(MIMAT0000770, SEQ ID N0.6); hsa-miR-139-5p(MIMAT0000250, SEQ ID N0.7); hsa-miR-142-3p(MIMAT0000434, SEQ ID N0.9); hsa-miR-142-5p(MIMAT0000433, SEQ ID N0.10); hsa-miR-148a(MIMAT0000243, SEQ ID N0.11); hsa-miR-148b(MIMAT0000759, SEQ ID N0.12); hsa-miR-17-5p(MIMAT0000070, SEQ ID N0.13); hsa-miR-191(MIMAT0000440, SEQ ID N0.14); hsa-miR-22(MIMAT0000077, SEQ ID N0.15); hsa-miR-223(MIMAT0000280, SEQ ID N0.16); hsa-miR-26a(MIMAT0000082, SEQ ID N0.17); hsa-miR-26b(MIMAT0000083, SEQ ID N0.18); hsa-miR-28-5p(MIMAT0000085, SEQ ID N0.19); hsa-miR-29a(MIMAT0000086, SEQ ID N0.20); hsa-miR-30b(MIMAT0000420, SEQ ID N0.21); hsa-miR-32(MIMAT0000090, SEQ ID N0.23); hsa-miR-328(MIMAT0000752, SEQ ID N0.24); hsa-miR-331-3p(MIMAT0000760, SEQ ID N0.25); hsa-miR-342-3p(MIMAT0000753, SEQ ID N0.26); hsa-miR-376a(MIMAT0000729, SEQ ID N0.28); hsa-miR-432-staR(MIMAT0002815, SEQ ID N0.29); hsa-miR-484(MIMAT0002174, SEQ ID N0.30); hsa-miR-486-5p(MIMAT0002177, SEQ ID N0.31); hsa-miR-566(MIMAT0003230, SEQ ID N0.32); hsa-miR-92a(MIMAT0000092, SEQ ID N0.33); hsa-miR-98(MIMAT0000096, SEQ ID N0.34)。9.如权利要求1或2所述的方法,其特征在于,所述检测步骤a)包括在来自所述对象 的生物液体样品中检测至少15个miRNA,其中所述至少15个miRNA是: hsa-let-7a(MIMAT0000062, SEQ ID N0.1); hsa-miR-133b(MIMAT0000770, SEQ ID N0.6); hsa-miR-342-3p(MIMAT0000753, SEQ ID N0.26); hsa-miR-486-5p(MIMAT0002177, SEQ ID N0.31);且其它11个miRNA包含在下组中:hsa-let-7b(MIMAT0000063, SEQ ID N0.2);hsa-let-7d(MIMAT0000065, SEQ ID N0.3);hsa-miR-103(MIMAT0000101, SEQ ID N0.4);hsa-miR-126(MIMAT0000445, SEQ ID N0.5);hsa-miR-139-5p(MIMAT0000250, SEQ ID N0.7);hsa-miR-140-5p(MIMAT0000431, SEQ ID N0.8);hsa-miR-142-3p(MIMAT0000434, SEQ ID N0.9);hsa-miR-142-5p(MIMAT0000433, SEQ ID N0.10);hsa-miR-148a(MIMAT0000243, SEQ ID N0.11);hsa-miR-148b(MIMAT0000759, SEQ ID N0.12);hsa-miR-17-5p(MIMAT0000070, SEQ ID N0.13);hsa-miR-191(MIMAT0000440, SEQ ID N0.14);hsa-miR-22(MIMAT0000077, SEQ ID N0.15);hsa-miR-223(MIMAT0000280, SEQ ID N0.16);hsa-miR-26a(MIMAT0000082, SEQ ID N0.17);hsa-miR-26b(MIMAT0000083, SEQ ID N0.18);hsa-miR-28-5p(MIMAT0000085, SEQ ID N0.19);hsa-miR-29a(MIMAT0000086, SEQ ID N0.20);hsa-miR-30b(MIMAT0000420, SEQ ID N0.21);hsa-miR-30c(MIMAT0000244, SEQ ID N0.22);hsa-miR-32(MIMAT0000090, SEQ ID N0.23);hsa-miR-328(MIMAT0000752, SEQ ID N0.24);hsa-miR-331-3p(MIMAT0000760, SEQ ID N0.25);hsa-miR-374a(MIMAT0000727, SEQ ID N0.27);hsa-miR-376a(MIMAT0000729, SEQ ID N0.28);hsa-miR-432-staR(MIMAT0002815, SEQ ID N0.29);hsa-miR-484(MIMAT0002174, SEQ ID N0.30);hsa-miR-566(MIMAT0003230, SEQ ID N0.32);hsa-miR-92a(MIMAT0000092, SEQ ID N0.33);hsa-miR-98(MIMAT0000096, SEQ ID N0.34)。10.如权利要求9所述的方法,其特征在于,所述至少15个miRNA是:hsa-let-7a(MIMAT0000062, SEQ ID N0.1);hsa-let-7b(MIMAT0000063, SEQ ID N0.2);hsa-let-7d(MIMAT0000065, SEQ ID N0.3);hsa-miR-133b(MIMAT0000770, SEQ ID N0.6); hsa-miR-139-5p(MIMAT0000250, SEQ ID N0.7);hsa-miR-140-5p(MIMAT0000431, SEQ ID N0.8);hsa-miR-148b(MIMAT0000759, SEQ ID N0.12);hsa-miR-17-5p(MIMAT0000070, SEQ ID N0.13);hsa-miR-26b(MIMAT0000083, SEQ ID N0.18);hsa-miR-29a(MIMAT0000086, SEQ ID N0.20);hsa-miR-32(MIMAT0000090, SEQ ID N0.23);hsa-miR-342-3p(MIMAT0000753, SEQ ID N0.26);hsa-miR-432-staR(MIMAT0002815, SEQ ID N0.29);hsa-miR-486-5p(MIMAT0002177, SEQ ID N0.31);hsa-miR-92a(MIMAT0000092, SEQ ID N0.33)?11.如权利要求1或3所述的方法,其特征在于,所述检测步骤a)包括在来自所述对象 的生物液体样品中检测至少15个miRNA,其中所述至少15个miRNA是: hsa-miR-140-5p(MIMAT0000431, SEQ ID N0.8); hsa-miR-30c(MIMAT0000244, SEQ ID N0.22); hsa-miR-374a(MIMAT0000727, SEQ ID N0.27); hsa-let-7b(MIMAT0000063, SEQ ID N0.2); 且其它11个miRNA包含在下组中: hsa-let-7a(MIMAT0000062, SEQ ID N0.1); hsa-let-7d(MIMAT0000065, SEQ ID N0.3); hsa-miR-103(MIMAT0000101, SEQ ID N0.4); hsa-miR-126(MIMAT0000445, SEQ ID N0.5); hsa-miR-133b(MIMAT0000770, SEQ ID N0.6); hsa-miR-139-5p(MIMAT0000250, SEQ ID N0.7); hsa-miR-142-3p(MIMAT0000434, SEQ ID N0.9); hsa-miR-142-5p(MIMAT0000433, SEQ ID N0.10); hsa-miR-148a(MIMAT0000243, SEQ ID N0.11); hsa-miR-148b(MIMAT0000759, SEQ ID N0.12); hsa-miR-17-5p(MIMAT0000070, SEQ ID N0.13); hsa-miR-191(MIMAT0000440, SEQ ID N0.14); hsa-miR-22(MIMAT0000077, SEQ ID N0.15); hsa-miR-223(MIMAT0000280, SEQ ID N0.16); hsa-miR-26a(MIMAT0000082, SEQ ID N0.17); hsa-miR-26b(MIMAT0000083, SEQ ID N0.18); hsa-miR-28-5p(MIMAT0000085, SEQ ID N0.19); hsa-miR-29a(MIMAT0000086, SEQ ID N0.20); hsa-miR-30b(MIMAT0000420, SEQ ID N0.21); hsa-miR-32(MIMAT0000090, SEQ ID N0.23); hsa-miR-328(MIMAT0000752, SEQ ID N0.24); hsa-miR-331-3p(MIMAT0000760, SEQ ID N0.25); hsa-miR-342-3p(MIMAT0000753, SEQ ID N0.26); hsa-miR-376a(MIMAT0000729, SEQ ID N0.28);hsa-miR-432-staR(MIMAT0002815, SEQ ID N0.29);hsa-miR-484(MIMAT0002174, SEQ ID N0.30);hsa-miR-486-5p(MIMAT0002177, SEQ ID N0.31);hsa-miR-566(MIMAT0003230, SEQ ID N0.32);hsa-miR-92a(MIMAT0000092, SEQ ID N0.33);hsa-miR-98(MIMAT0000096, SEQ ID N0.34)。12.如权利要求1或2所述的方法,其特征在于,所述检测步骤a)包括在来自所述对象 的生物液体样品中检测至少20个miRNA,其中所述至少20个miRNA是: hsa-let-7a(MIMAT0000062, SEQ ID N0.1); hsa-miR-133b(MIMAT0000770, SEQ ID N0.6); hsa-miR-342-3p(MIMAT0000753, SEQ ID N0.26); hsa-miR-486-5p(MIMAT0002177, SEQ ID N0.31); 且其它16个miRNA包含在下组中: hsa-let-7b(MIMAT0000063, SEQ ID N0.2); ...
【专利技术属性】
技术研发人员:F·比安基,F·尼卡西奥,M·J·L·N·马尔奇,P·迪费奥雷,
申请(专利权)人:意大利癌症研究基金会分子肿瘤学研究所IFOM,欧洲肿瘤研究所有限公司,米兰大学,
类型:发明
国别省市:意大利;IT
还没有人留言评论。发表了对其他浏览者有用的留言会获得科技券。